Form 4: TELA Bio Director Lisa Colleran Receives Significant Equity Grant, Aligning Interests with Shareholders

TELA Bio, Inc. Director Lisa N. Colleran was granted 7,950 restricted stock units and options to purchase 11,700 shares of common stock, aligning her interests with shareholders.

Summary

• Lisa N. Colleran, a Director of TELA Bio, Inc. (TELA), was granted equity awards on May 28, 2025.
• She acquired 7,950 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs will vest on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, contingent on her continued service.
• Additionally, she was granted options to purchase 11,700 shares of common stock with an exercise price of $1.39 per share.
• These stock options also vest on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, subject to her continued service.
• Following these transactions, Ms. Colleran beneficially owns 18,470 shares of common stock and 11,700 stock options.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. While there's potential for dilution, it's a standard compensation practice.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The vesting conditions, tied to continued service, incentivize long-term commitment from the director.
• The acquisition of equity by an insider can be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The issuance of new equity awards, particularly stock options, can lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the granted equity awards is subject to market fluctuations, and there is no guarantee of future appreciation.
• The vesting of these awards is contingent on the director's continued service, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The document indicates future vesting events for the granted equity awards, contingent on the director's continued service through May 28, 2026, or the next annual meeting of stockholders, or a Change in Control. The stock options have an expiration date of May 28, 2035.

Industry Context

This is a standard equity grant to a director, common practice in publicly traded companies across various industries to align director incentives with shareholder value. It does not provide specific industry trends or competitive analysis.

Comparison to Industry Standards

• Granting equity awards (RSUs and stock options) to non-employee directors is a common compensation practice across industries, including the medical technology sector where TELA Bio operates.
• The vesting schedule tied to continued service and potential acceleration upon a Change in Control is typical for such awards, aiming to retain talent and incentivize performance.
• The specific number of shares and options granted would typically be benchmarked against peer companies of similar size and stage within the medical device or biotech industry, though this document does not provide such comparative data.

Related Party Transactions

• The equity grant to Lisa N. Colleran, a director of TELA Bio, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if stock options are exercised, but also improved alignment of director's interests with shareholder value.
• Employees: The equity incentive plan mentioned (Amended and Restated 2019 Equity Incentive Plan) suggests a broader framework for employee incentives, potentially boosting morale and retention.
• Management: The director's compensation structure is aligned with company performance, incentivizing strategic decisions that enhance shareholder value.

Next Steps

• Vesting of 7,950 restricted stock units on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control.
• Vesting of 11,700 stock options on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control.
• Potential exercise of stock options by May 28, 2035, if vested and in-the-money.

Key Dates

Recommendation

Keywords

TELA Bio, TELA, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance, Beneficial Ownership